MEMBER PREVIEW
The action stops new-patient use and sales while authorities review concerns about the principal study behind the rare-disease medicine’s approval.
IMPORTANT INTELLIGENCE · ₹99 / ₹199
THE INVESTOR ANALYSIS CONTINUES BEHIND THE GRID.
Unlock the full analysis, investor takeaways, risk map, watch points and source record with IMG Premium. The ₹199 plan also includes Grid Minds, Investor Lens podcasts, In Brief and the daily morning and evening PDFs.
Continue to membership in your browser ↗Informational research only. No personalised recommendation or assured-return claim.